OCTIMET Oncology
-
2016
Company Description
OCTIMET has licensed from Janssen Pharmaceutica, highly selective MET kinase inhibitors with clean safety profiles
OCTIMET oncology’s overall strategy is to advance the development of discovery stage molecules by employing innovative patient selection and pharmacodynamic biomarker-based strategies, as well as an innovative clinical development strategy.
-
Manufacturer:
Science and Engineering -
Formed:
2016 -
Company Website:
-
Company E-mail:
-
Company Address:
Turnhoutseweg 30BeerseBelgium -
CEO:
- Tim Perera
-
We recognize our sponsors starting at $1 per entry.
Learn more at https://www.ithistory.org/benefits